| Date | Acquired company | Acquiring company | Amount | Related |
|---|---|---|---|---|
| 2018-07-23 | TxCell (France) | Sangamo Therapeutics (USA - CA) | € 72 million | Cell therapy - CAR-T - Immunological diseases |
| 2018-07-19 | Agilis Biotherapeutics (USA - MA) | PTC Therapeutics (USA - NJ) | up to $260 million and success-based milestones | Rare diseases - CNS Diseases - Gene therapy |
| 2018-06-16 | Interactive Biosoftware (Frane) | Sophia Genetics (France - Switzerland) | undisclosed | |
| 2018-05-15 | Avexis (USA - IL) | Novartis (Switzerland) | $ 8.7 billion | Gene therapy - Neurodegenerative diseases - CNS diseases |
| 2018-05-14 | AurKa Pharma (Canada) | Eli Lilly (USA - IN) | up to $575 million | Cancer - Oncology |
| 2018-05-10 | ARMO BioSciences (USA - CA) | Eli Lilly (USA - IN) | $1.6 billion | Cancer - Oncology |
| 2018-04-16 | Shire's oncology business (UK-USA) | Servier (France) | $2.4 billion (€1.94 billion) | |
| 2018-02-21 | Viralytics (Australia) | Merck&Co (USA - NJ) | $394 million | Cancer - Oncology |
| 2018-02-20 | Clinical Assistance Programs (CAP) (USA - MA) | Alira Health (France - Germany - Italy - Spain - USA) | undisclosed | Technology - Services |
| 2018-02-01 | Advanced Accelerator Applications (France) | Novartis (Switzerland) | $3.9 billion | Cancer - Oncology |
| 2018-01-29 | Ablynx (Belgium) | Sanofi (France) | €3.9 billion | Hematological diseases - Inflammatory diseases |
| 2018-01-22 | Bioverativ (USA - CA) | Sanofi (France) | $11.6 billion (€ 9.47 billion) | Rare diseases - Genetic diseases - Hematological diseases |
| 2018-01-22 | Juno Therapeutics (USA - WA) | Celgene (USA _ NJ) | $9 billion (€ 7.34 billion) | Cancer - Oncology - Hematological diseases |
| 2018-01-08 | Ablynx (Belgium) | Novo Nordisk (Denmark) | € 2.6 billion | Hematological diseases - Inflammatory diseases |
| 2018-01-05 | Tigenix (Belgium) | Takeda Pharmaceutical (Japan) | € 520 million | |
| 2017-12-29 | Sellas Life Sciences (Bermuda) | Galena BioPharma (USA - OR) | Cancer - Oncology | |
| 2017-12-26 | Sucampo Pharmaceuticals (USA - MA) | Mallinckrodt (UK) | $1.2 Billion | Rare diseases |
| 2017-12-23 | Discuva (UK) | Summit (UK) | £10 million | Infectious diseases |
| 2017-12-21 | Ignyta (USA - CA) | Roche (Switzerland) | $ 1.7 billion | Cancer - Oncology |
| 2017-12-21 | Pasteur Group (Brazil) | Eurofins Scientific (Luxembourg) | undisclosed | Diagnostic |
